Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT01117623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT01117623
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Interventions
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg Drug
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg Drug
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg Drug
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg Drug
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg Drug
- HCC Child-Pugh A expansion cohort: Regorafenib 100 mg Drug
- HCC Child-Pugh B expansion cohort: Regorafenib 100 mg Drug
- NSCLC expansion cohort: Regorafenib 100 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
- Last update posted
- Nov 17, 2015
2007 – 2013
United States locations
- U.S. sites
- 5
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78229-3307 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01117623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2015 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01117623 live on ClinicalTrials.gov.